<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bacterial infections following lung transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bacterial infections following lung transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bacterial infections following lung transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aimee Zaas, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott M Palmer, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julia A Messina, MD, MHS, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramsey R Hachem, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lung transplantation is an effective treatment for a wide range of advanced lung diseases. While the survival of lung transplant recipients continues to improve, outcomes after lung transplantation remain inferior to other types of solid organ transplantation [<a href="#rid1">1,2</a>]. Infectious complications contribute substantially to morbidity and mortality following lung transplantation and account for over 25 percent of all post-transplant deaths [<a href="#rid2">2</a>].</p><p>This topic reviews the most common bacterial infections in lung transplant recipients. Infections caused by fungi, mycobacteria, and viruses in lung transplant recipients and general issues regarding infections in solid organ transplant recipients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">"Evaluation for infection before solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">"Prophylaxis of infections in solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">RISK OF INFECTION</span><span class="headingEndMark"> — </span>Lung transplant recipients are at increased risk for infectious complications due to the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The high level of immunosuppression required to prevent rejection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects of transplantation on local pulmonary host defenses (loss of lymphatics, reduced mucociliary clearance, decreased cough)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Constant environmental contact allowing pathogens direct access into the allograft</p><p></p><p>The likelihood and type of infection varies with the degree of host immunosuppression, timing since transplantation, nature and duration of antimicrobial prophylaxis, and local hospital and regional microbiology.</p><p>Pneumonia, particularly bacterial pneumonia, is the most common type of infection in lung transplant recipients, although bloodstream, pleural space, and wound infections are also common [<a href="#rid3">3,4</a>]. Bacterial, viral, fungal, and mycobacterial infections all occur at an increased frequency after lung transplantation. (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p>In addition to the direct morbidity and mortality caused by infectious complications, they may also lead to loss of allograft function and contribute to the development of bronchiolitis obliterans syndrome [<a href="#rid5">5-7</a>]. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a>.)</p><p class="headingAnchor" id="H1627022150"><span class="h1">TIMELINE OF INFECTION</span><span class="headingEndMark"> — </span>Infections are generally thought to arise in a predictable pattern following solid organ transplantation, though deviations occur. The post-transplant period can be divided into three stages: the first month post-transplant, one to six months post-transplant, and more than six months post-transplant.</p><p class="bulletIndent1"><span class="glyph">●</span>During the early post-transplant period, bacterial infections predominate. During the first month, there are three major causes of infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection transmitted with the donor allograft</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection derived from the recipient</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infectious complications of the transplant surgery and hospitalization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>From one to six months post-transplant, patients are most at risk for opportunistic infections, although residual donor-derived infections arising from the perioperative period can persist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More than six months post-transplant, most patients are receiving stable and reduced levels of immunosuppression. These patients are subject to pneumonia caused by an extended range of bacteria, including pneumococcus, gram-negative bacilli, <em>Legionella</em>, and other common pathogens rather than opportunistic infections.</p><p></p><p>The pattern of infection seen during these periods is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'Timing of infection post-transplantation'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">EVALUATION FOR INFECTION</span><span class="headingEndMark"> — </span>Evaluation for infection in lung transplant recipients should follow the general approach used in all solid organ transplant recipients. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'Evaluation and management'</a>.)</p><p>Several unique considerations apply to lung transplant recipients in whom pneumonia is the most common type of infection [<a href="#rid3">3</a>]. Some lung transplant recipients with pneumonia present with fever, cough, dyspnea, and infiltrates on chest imaging. However, some patients have few or atypical symptoms due to the blunting of the immune response by immunosuppressive drugs. In addition, the presentation of infection often overlaps with that of allograft rejection; thus, a high index of suspicion for both infection and rejection should be maintained to ensure early appropriate diagnosis and therapy. (See  <a class="medical medical_review" href="/z/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a>.)</p><p class="headingAnchor" id="H1627022190"><span class="h2">Diagnostic approach</span><span class="headingEndMark"> — </span>Since pneumonia is the most common type of infection in lung transplant recipients, the diagnostic evaluation generally includes early and aggressive evaluation of the lungs as a potential source. Lung transplant recipients can deteriorate quickly in the absence of appropriate therapy. Thus, a reasonable approach to the lung transplant patient with respiratory symptoms involves initial empiric treatment for infection while awaiting microbiologic and histopathologic data. The specific organisms targeted by the empiric regimen depend upon the patient's risk factors and clinical presentation. (See <a class="local">'Treatment'</a> below.)</p><p>After initiation of empiric antimicrobial therapy and imaging with a chest radiograph, invasive diagnostic testing should be considered in most lung transplant recipients unless contraindications exist. In addition, chest computed tomography may be helpful in patients when a pulmonary infection is uncertain based on clinical history, exam, and chest radiographs alone.</p><p>Bronchoscopy with bronchoalveolar lavage is the most sensitive diagnostic study to identify the etiology of pulmonary infections and rule out atypical etiologies  (<a class="graphic graphic_table graphicRef70685" href="/z/d/graphic/70685.html" rel="external">table 1</a>). Due to the similar clinical presentation, we normally perform transbronchial biopsies at the same time to rule out rejection [<a href="#rid8">8</a>]. In addition, it is possible that infection and rejection may coexist.</p><p class="headingAnchor" id="H1627022209"><span class="h1">BACTERIAL INFECTIONS</span><span class="headingEndMark"> — </span>Bacterial infection is the most common early infectious complication after lung transplantation and remains a leading cause of death throughout the post-transplant period [<a href="#rid9">9,10</a>]. In addition to pneumonia, lung transplant recipients are at risk for other types of bacterial infections including empyema, bloodstream infection, and wound infection.</p><p class="headingAnchor" id="H1627022221"><span class="h2">Sites of infection</span></p><p class="headingAnchor" id="H1627022228"><span class="h3">Pneumonia</span><span class="headingEndMark"> — </span>The risk for the development of bacterial pneumonia is influenced by both donor and recipient factors, and the risk is highest during the early post-transplant period. Despite antibiotic prophylaxis, the incidence of bacterial pneumonia is approximately 10 to 20 percent in the first 30 days post-transplant [<a href="#rid11">11,12</a>]. In a prospective multicenter study of pneumonia in lung transplant recipients, 40 of 85 episodes of pneumonia (44 percent) occurred during the first 30 days following transplantation [<a href="#rid13">13</a>]. Early post-transplant pneumonias are typically caused by hospital-acquired bacteria, including multidrug-resistant <em>Pseudomonas aeruginosa</em>, Enterobacteriaceae, and methicillin-resistant <em>Staphylococcus aureus</em>. (See  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p>Bacterial infections can be transmitted from the donor or develop in the setting of the post-transplant intensive care unit admission. Although approximately 60 percent of donor lungs are colonized, only 6 to 12 percent of recipients develop active infection transmitted from the donor lungs if they receive appropriate antibiotic prophylaxis [<a href="#rid12">12,14</a>]. The detection of certain bacteria from the donor lung(s) warrants additional antibacterials beyond the usual period of perioperative prophylaxis, as discussed below. (See <a class="local">'Routine perioperative prophylaxis'</a> below and <a class="local">'Positive donor lung cultures'</a> below.)</p><p>Later in the time course (especially more than six months post-transplant), lung transplant recipients are also at risk for developing pneumonia from community-acquired bacterial pathogens. In addition, the risk for infection with multidrug-resistant bacteria remains elevated due to the transplant recipient's frequent exposure to health care facilities and increased use of antibacterial agents. (See  <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p>In addition to the usual community-acquired and hospital-acquired pathogens, lung transplant recipients are at increased risk for pneumonia with bacteria that are typically nonpathogenic in the immunocompetent host, such as <em>Mycoplasma hominis</em> [<a href="#rid15">15</a>], <em>Ureaplasma urealyticum </em>[<a href="#rid16">16</a>], and <em>Nocardia</em> spp [<a href="#rid17">17-20</a>], and, for fungal pneumonia, most commonly caused by <em>Aspergillus fumigatus</em>. <em>M. hominis </em>has been reported as donor derived [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a>.)</p><p>Lung transplantation recipients are also at increased risk for aspiration pneumonia, both in the early post-transplant period and thereafter. This risk is enhanced in the early postoperative period due to oropharyngeal dysfunction, surgical irritation or damage to the phrenic nerve, and resultant delay in gastric emptying that could persist for weeks. In addition, underlying disorders that impair esophageal function (eg, scleroderma) and/or airway protection (eg, stroke) may coexist. (See  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a>.) </p><p>Patients with cystic fibrosis (CF) are at a significantly higher risk of pneumonia compared with other lung transplant recipients [<a href="#rid11">11,22</a>] and are more likely to be colonized with multidrug-resistant <em>P. aeruginosa</em> and <em>Burkholderia cepacia</em> [<a href="#rid23">23</a>]. Despite a decreased bacterial burden after removal of the native lungs, patients with CF are at high risk of post-transplant infection due to the potential for contamination of the bloodstream and the thoracic cavity during transplantation. Furthermore, these patients remain at increased risk for infection post-transplant because the native upper airways and sinuses of CF patients retain the chloride channel defect and remain persistently colonized with the pathogens that were present pre-transplant, particularly <em>P. aeruginosa</em> and <em>B. cepacia</em>. (See <a class="local">'Pseudomonas aeruginosa'</a> below and <a class="local">'Burkholderia cepacia'</a> below and  <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a> and  <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a>.)</p><p class="headingAnchor" id="H1627022241"><span class="h3">Pleural space infections</span><span class="headingEndMark"> — </span>Reaccumulation of pleural fluid after the initial post-transplant chest tube removal can occur due to hemorrhage, rejection, or infection. Pleural fluid accumulation that worsens beyond the first few days following transplantation warrants immediate investigation to exclude empyema [<a href="#rid24">24</a>]. Empyema occurs in 3 to 5 percent of lung transplant recipients; almost all of these infections occur during the first six months after transplantation, with 40 percent occurring within the first month [<a href="#rid25">25-28</a>]. In one large single-center study, pleural disease occurred in a bimodal occurrence after lung transplantation, with earlier disease more likely to be infectious than pleural disease occurring greater than one year after transplant [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p>The incidence of pleural space infections does not appear to be dependent on underlying lung disease or surgical procedure [<a href="#rid25">25,30,31</a>]. However, case reports show an increased incidence of pleural space infections due to <em>B. cepacia</em> in patients with cystic fibrosis who harbor this organism pre-transplant [<a href="#rid32">32</a>]. In a study of pleural space infections in 36 lung transplant recipients, the most common causes were fungi (in 61 percent) and bacteria (in 31 percent) [<a href="#rid31">31</a>]. No bacterial species predominated; there were two cases each of <em>B. cepacia</em>, <em>Escherichia coli</em>, and <em>Mycoplasma hominis</em>, and one case each of <em>S. aureus</em>, <em>Enterococcus </em>spp, <em>P. aeruginosa</em>, <em>Serratia marcescens</em>, and <em>Roseomonas </em>spp. <em>Listeria monocytogenes</em>, which rarely causes pneumonia, has been reported as a cause of empyema in a lung transplant recipient [<a href="#rid33">33</a>].</p><p>The short-term mortality of lung transplant recipients with empyema has been estimated to approach 40 percent [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H1627022254"><span class="h3">Bloodstream infections</span><span class="headingEndMark"> — </span>Bloodstream infections (BSIs) are an important cause of morbidity and mortality in lung transplant recipients. In a prospective multicenter study of lung transplant recipients over a five-year period, the incidence of bacteremia was 11.5 percent [<a href="#rid34">34</a>]. Risks for BSI include the use of central venous catheters, mechanical ventilation, and cystic fibrosis. BSIs in transplant recipients reflect the pattern of bloodstream infections in immunocompetent hospitalized patients and are most frequently due to <em>S. aureus</em>, <em>P. aeruginosa</em>, <em>Enterococcus </em>spp, and <em>Candida </em>spp [<a href="#rid35">35</a>]. In another prospective multicenter study, pulmonary and vascular catheter infections accounted for 47 and 41 percent of all BSIs after lung transplant, respectively [<a href="#rid34">34</a>]. The lungs were the predominant source of BSIs in the first year post-transplant, whereas vascular catheters predominated as the source after one year. Resistant gram-negative bacteremia was more likely with underlying pneumonia and in patients with cystic fibrosis. (See  <a class="medical medical_review" href="/z/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/z/d/html/2139.html" rel="external">"Epidemiology of Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a>.)</p><p>The development of BSI is associated with increased mortality for both adult and pediatric lung transplant recipients [<a href="#rid35">35,36</a>]. In a multivariate analysis, BSI was associated with an almost sixfold increased risk of death [<a href="#rid35">35</a>]. Blood cultures should be obtained in all lung transplant recipients presenting with pneumonia or any systemic signs or symptoms of infection following transplantation.</p><p class="headingAnchor" id="H1627022267"><span class="h3">Skin and soft tissue infections</span><span class="headingEndMark"> — </span>Although the high degree of immunosuppression places lung transplant recipients at risk for infection of the transplant surgical site, this occurs infrequently. The same nosocomial pathogens that cause early post-transplant bloodstream and lung infections (eg, <em>P. aeruginosa</em>, <em>S. aureus</em>, <em>Candida </em>spp) are the most common causes of surgical wound infections [<a href="#rid37">37</a>]. <em>P. aeruginosa</em> and nontuberculous mycobacteria (especially <em>Mycobacterium abscessus</em>) are of particular concern in patients with cystic fibrosis due to pretransplant colonization or chronic infection with those organisms and the risk for perioperative seeding of the surgical wound [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p><em>M. hominis</em> and <em>U. urealyticum </em>are rare but reported causes of surgical wound infection after lung transplantation [<a href="#rid40">40,41</a>]. Unexplained hyperammonemia can be a clue to diagnosis [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H1627022279"><span class="h2">Specific pathogens</span><span class="headingEndMark"> — </span>Lung transplant recipients are susceptible to a broad range of gram-positive and gram-negative infections.</p><p>Patients with cystic fibrosis have unique risk factors for infection following transplantation. In particular, patients with CF are often colonized with methicillin-resistant <em>S. aureus</em> as well as such gram-negative bacteria as <em>P. aeruginosa</em> and <em>B. cepacia</em>, both of which are frequently multidrug resistant. The reported incidence of nontuberculous mycobacteria is also increasing, particularly among lung transplant recipients with cystic fibrosis. (See <a class="local">'Nontuberculous mycobacteria'</a> below.)</p><p>While certain viral and fungal infections have been associated with an increased risk for chronic lung allograft dysfunction (CLAD), and specifically to the bronchiolitis obliterans phenotype, the role of bacterial pathogens in the development of CLAD remains uncertain. Some reports suggest an association between <em>P. aeruginosa </em>and <em>Chlamydia pneumoniae </em>and a higher incidence of chronic lung rejection, though those results have not been consistently replicated [<a href="#rid43">43,44</a>]. (See <a class="local">'Chlamydia pneumoniae'</a> below and  <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a>.)</p><p>Microbiome sequencing is being used to help determine role of the respiratory microbiota in the development of CLAD. In a prospective cohort study evaluating bronchoalveolar lavage (BAL) fluid from lung transplant recipients one year post-transplant, investigators found that increased bacterial burden within the BAL fluid was predictive of the development of CLAD at 500 days post-transplant [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H1627022286"><span class="h3">Pseudomonas aeruginosa</span><span class="headingEndMark"> — </span>Nearly 50 percent of <em>Pseudomonas</em> isolates in lung transplant recipients are resistant to one or more antibiotics [<a href="#rid46">46</a>]. While the safety of lung transplantation in patients colonized or chronically infected with multidrug-resistant pathogens has been a matter of controversy since the beginning of lung transplantation, an increasing number of studies has shown acceptable survival for lung transplantation in patients colonized with multidrug-resistant gram-negative bacteria prior to transplant [<a href="#rid47">47-50</a>]. As an example, in one retrospective study, one-year survival for CF patients colonized with multidrug-resistant <em>P. aeruginosa</em> was greater than 80 percent and was similar to other patients with CF who were not colonized with resistant bacteria [<a href="#rid47">47</a>]. Based on these findings, pretransplant colonization with multidrug-resistant <em>P. aeruginosa</em> should not exclude patients from consideration for transplant. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p class="headingAnchor" id="H1627022308"><span class="h3">Burkholderia cepacia</span><span class="headingEndMark"> — </span><em>B. cepacia</em> (formerly known as <em>Pseudomonas cepacia</em>) is a gram-negative rod that commonly colonizes the lungs of patients with cystic fibrosis and is frequently multidrug resistant [<a href="#rid51">51</a>]. <em>B. cepacia</em> has been classified into nine genomovars, which are phenotypically similar but genotypically distinct [<a href="#rid52">52</a>]. <em>Burkholderia cenocepacia</em> (genomovar III) and <em>Burkholderia multivorans </em>(genomovar II) are the most common causes of <em>B. cepacia</em> colonization and infection in CF patients, although the prevalence of each genomovar varies by geographic region. (See  <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a>.)</p><p>It has been shown that pretransplant <em>B. cepacia</em> colonization is associated with higher early post-transplant mortality [<a href="#rid47">47,53-55</a>]. However, subsequent studies have suggested that increased post-transplant mortality is associated only with <em>B. cenocepacia</em> (genomovar III) but not with <em>B. multivorans</em> (genomovar II) or other genomovars [<a href="#rid52">52-57</a>]. </p><p>In a study of 75 lung transplant recipients with CF, 7 were colonized with <em>B. cenocepacia</em>, 9 were colonized with other genomovars of <em>B. cepacia</em>, and 59 were not colonized with <em>B. cepacia</em> pretransplant [<a href="#rid52">52</a>]. One-year survival of patients with <em>B. cenocepacia</em> was 29 percent, compared with 89 percent for those with other <em>B. cepacia</em> genomovars and 92 percent for those without <em>B. cepacia</em>. A single center reviewed 216 patients with CF who underwent lung transplantation. Of these, 22 had confirmed preoperative <em>B. cepacia</em> complex<em> </em>(BCC) infection, with 12 of these being <em>B. cenocepacia</em>. Nine <em>B. cenocepacia</em>-infected recipients died within the first year, and in eight recipients, BCC sepsis was considered to be the cause of death. Despite instituting a tailored perioperative immunosuppressive and microbiologic care approach for such patients, post-transplantation BCC septic deaths occurred frequently in those with pretransplantation <em>B. cenocepacia</em> infection. In contrast, recipients infected with other BCC species had significantly better outcomes, with post-transplantation survival comparable to other recipients with CF [<a href="#rid55">55</a>]. Later complications of <em>B. cepacia</em> colonization include lung abscess and empyema.</p><p><em>Burkholderia dolosa</em> (genomovar VI) is a less common genomovar. In a retrospective study of 11 patients transplanted with known colonization with <em>B. dolosa,</em> survival rates were 73, 53, and 30 percent for 1, 3, and 5 years, respectively, with a median survival of 44 months. While survival appears lower than patients without pretransplant <em>Burkholderia</em> colonization, it remains notably higher than historical survival with <em>B. cenocepacia </em>[<a href="#rid53">53</a>].</p><p>Available data support screening of all patients with CF for <em>B. cenocepacia</em>. Colonization with this strain is viewed as a relative contraindication to transplantation. If transplantation is attempted in patients who harbor <em>B. cenocepacia</em>, early aggressive antimicrobial prophylaxis should be employed in an effort to decrease early <em>B. cepacia</em>-related mortality. (See <a class="local">'Positive native lung cultures'</a> below.)</p><p class="headingAnchor" id="H604872"><span class="h3">Other gram-negative bacteria</span><span class="headingEndMark"> — </span>In addition to <em>P. aeruginosa</em> and <em>B. cepacia</em>, other gram-negative bacteria species can cause pneumonia in lung transplant recipients, some of which are multidrug resistant [<a href="#rid58">58</a>]. Commonly encountered gram-negative species include <em>Acinetobacter</em> spp, <em>Stenotrophomonas maltophilia</em>, <em>Klebsiella pneumoniae</em>, <em>Enterobacter cloacae</em>, <em>Serratia marcescens</em>, and <em>E. coli</em> [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3150.html" rel="external">"Acinetobacter infection: Treatment and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/13961.html" rel="external">"Stenotrophomonas maltophilia"</a> and  <a class="medical medical_review" href="/z/d/html/3122.html" rel="external">"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection"</a> and  <a class="medical medical_review" href="/z/d/html/87709.html" rel="external">"Infections due to <i>Serratia </i>species"</a> and  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a>.)</p><p class="headingAnchor" id="H604897"><span class="h3">Staphylococcus aureus</span><span class="headingEndMark"> — </span><em>S. aureus</em>, including methicillin-resistant <em>S. aureus</em>, is a common cause of hospital-acquired, health care-associated, and ventilator-associated pneumonia, as well as bacteremia and surgical-site infections [<a href="#rid59">59</a>]. Specific infections caused by <em>S. aureus</em> are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3157.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology"</a> and  <a class="medical medical_review" href="/z/d/html/2139.html" rel="external">"Epidemiology of Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H1627022321"><span class="h3">Streptococcus pneumoniae</span><span class="headingEndMark"> — </span>Lung transplant recipients in the late post-transplant period (more than six months following transplantation) are susceptible to typical community-acquired pathogens such as <em>Streptococcus pneumoniae</em>. Despite the use of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> for <em>Pneumocystis</em> prophylaxis, lung transplant recipients have a greater likelihood of developing invasive pneumococcal infection and bacteremia [<a href="#rid60">60</a>]. In addition, they have an increased incidence of infection with resistant <em>S. pneumoniae</em>, with approximately 80 percent of isolates resistant to trimethoprim-sulfamethoxazole and 60 percent with intermediate- or high-level penicillin resistance [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/7013.html" rel="external">"Pneumococcal pneumonia in patients requiring hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p>All adult lung transplant candidates and recipients in the United States should be vaccinated against pneumococcus  (<a class="graphic graphic_table graphicRef86782" href="/z/d/graphic/86782.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p class="headingAnchor" id="H1627022334"><span class="h3">Chlamydia pneumoniae</span><span class="headingEndMark"> — </span>The obligate intracellular bacteria <em>C. pneumoniae</em> can cause upper and lower respiratory tract infections. Due to the difficulty in culturing <em>Chlamydia</em>, diagnosis relies on serological and molecular techniques. These limitations have led to an underestimation of the frequency of <em>Chlamydia</em> infection in the early post-transplant period.</p><p>One study employed polymerase chain reaction (PCR) for <em>Chlamydia</em> on BAL fluid in lung transplant recipients during the early post-transplant period. A positive PCR for <em>Chlamydia</em> was identified in 25 percent of patients within the first month post-transplant [<a href="#rid61">61</a>]. The identification of <em>Chlamydia</em> spp was associated with adverse outcomes, including allograft rejection, airway complications, and increased mortality. In addition, possible donor transmission of <em>Chlamydia</em> was observed in three patients. Until newer diagnostic techniques are widely available, clinicians must have a high index of suspicion for this underappreciated pathogen in lung transplant recipients.</p><p class="headingAnchor" id="H1627022347"><span class="h3">Nocardia</span><span class="headingEndMark"> — </span>Infections caused by <em>Nocardia</em> species are rare. The majority of cases occur in immunocompromised patients, including solid organ transplant recipients. Approximately 1.9 to 3.5 percent of lung transplant recipients develop nocardiosis [<a href="#rid17">17,18,62</a>], with a mean onset of 14.3 months after transplantation (range 1.5 to 39 months) [<a href="#rid17">17</a>]. Although <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> has activity against <em>Nocardia</em> species, cases of nocardiosis have occurred in patients receiving thrice-weekly trimethoprim-sulfamethoxazole prophylaxis, and thus daily trimethoprim-sulfamethoxazole may be more effective at preventing this infection [<a href="#rid17">17,18</a>]. <em>Nocardia</em> species most commonly cause pneumonia in lung transplant recipients, typically with a subacute presentation [<a href="#rid19">19</a>].</p><p>Nocardiosis should be considered in lung transplant recipients with pneumonia, particularly if it does not respond to empiric therapy. Special staining (modified acid-fast bacillus staining) and cultures should be requested when infection with <em>Nocardia</em> spp is suspected  (<a class="graphic graphic_table graphicRef70685" href="/z/d/graphic/70685.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">"Nocardia infections: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5513.html" rel="external">"Treatment of nocardiosis"</a> and  <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">"Nocardia infections: Epidemiology, clinical manifestations, and diagnosis", section on 'Lungs'</a>.)</p><p class="headingAnchor" id="H1627022359"><span class="h3">Clostridioides difficile</span><span class="headingEndMark"> — </span><em>Clostridioides</em> <em>difficile</em> infection is a common problem in lung transplant recipients, with an estimated incidence of 7 to 31 percent [<a href="#rid63">63-65</a>]. <em>C. difficile</em> infection occurs most frequently in the early period following transplantation and in those requiring prolonged hospitalization. The intense immunosuppression and frequent exposure to antimicrobial agents that occur shortly after transplantation likely contribute to the increased risk for <em>C. difficile</em> infection during this period [<a href="#rid64">64</a>]. In a single-center retrospective analysis of 500 lung transplant recipients, 6 percent developed <em>C. difficile</em> infections within 90 days of postoperative antimicrobial prophylaxis [<a href="#rid66">66</a>]. The duration of antibiotics with gram-positive activity and intensive care unit stay appeared to increase the risk. In another study, <em>C. difficile</em> infection was an independent predictor of death among lung transplant recipients, especially if it occurred in the first six months post-transplant [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology"</a> and  <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H102000206"><span class="h3">Mycoplasma hominis, Ureaplasma urealyticum, and hyperammonemia</span><span class="headingEndMark"> — </span>Severe hyperammonemia has been reported as a rare and frequently fatal cause of coma in lung transplant recipients during the early postoperative period. Some cases of hyperammonemia in lung transplant recipients have been associated with <em>Mycoplasma</em> or <em>Ureaplasma</em> infection. The clinical manifestations, diagnosis, and treatment of <em>M.</em> <em>hominis</em> and <em>Ureaplasma</em> spp infections in lung transplant recipients with hyperammonemia are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation", section on 'Hyperammonemia'</a> and  <a class="medical medical_review" href="/z/d/html/5508.html" rel="external">"<i>Mycoplasma hominis</i> and <i>Ureaplasma </i>infections", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H4095489294"><span class="h3">Nontuberculous mycobacteria</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria are increasingly recognized as causes of infections in lung transplant recipients [<a href="#rid38">38,68-70</a>]. <em>Mycobacterium avium</em> and <em>Mycobacterium intracellulare</em> (together known as <em>M. avium</em> complex [MAC]) are the most common nontuberculous mycobacterial (NTM) species isolated after solid organ transplantation and infection with these organisms typically involves the lungs. Cutaneous and disseminated infections are the next most common presentations; however, the clinical presentation and severity of illness vary with the infecting NTM species and site(s) of involvement. (See  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H1627022723"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Empiric therapy should be based on prior culture data when available and antibiotics adjusted as needed by repeat cultures when possible.</p><p class="headingAnchor" id="H604798"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>In lung transplant recipients, the immunocompromised status, commonness of multidrug-resistant (MDR) bacteria, and higher risk of mortality outweigh any other factors related to whether they are community dwelling, hospitalized, or ventilated. As such, we do not find the distinction among types of pneumonia as community acquired, hospital acquired, or ventilator associated to be as helpful in this patient population.</p><p>We favor empiric broad-spectrum antibiotics initially, taking into account prior infections and colonization as well as other likely potential pathogens, including methicillin-resistant <em>S. aureus </em>(MRSA), <em>P. aeruginosa</em>, other gram-negative bacilli, and atypical bacteria (eg, <em>Mycoplasma pneumoniae</em>, <em>Legionella</em> spp). Bronchoalveolar lavage (BAL) cultures and other diagnostic tests (eg, <em>Legionella</em> urinary antigen, pneumococcal urinary antigen) should be used to adjust antibiotic regimens as appropriate. Even if a specific microbiologic etiology is not identified, continued broad-spectrum antibiotics may remain necessary in certain cases. A high index of suspicion for nonbacterial etiologies is needed when there is no clinical improvement despite appropriate antibiotics.</p><p>The diagnosis and treatment of pneumonia as well as the approach to the patient with nonresolving pneumonia are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">"Nonresolving pneumonia"</a>.)</p><p class="headingAnchor" id="H13586014"><span class="h3">Duration</span><span class="headingEndMark"> — </span>There are no high-quality data to guide the duration of antibiotic therapy for bacterial pneumonia in lung transplant recipients. Short-course antibiotic therapy for seven or eight days has only been validated in the immunocompetent host with ventilator-associated pneumonia [<a href="#rid71">71</a>]. In most cases, two weeks of antibiotics is an appropriate duration for lung transplant recipients with bacterial pneumonia. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Duration'</a>.)</p><p class="headingAnchor" id="H13586003"><span class="h2">Other infections</span><span class="headingEndMark"> — </span>The treatment of pleural space infections in lung transplant recipients requires drainage as well as a prolonged course of antimicrobial therapy. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p>Some skin and soft tissue infections require surgical debridement as well as prolonged antibiotics. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a>.)</p><p>The general approach to bloodstream infections is similar as the approach in nontransplant patients. (See  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3168.html" rel="external">"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a> and  <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1627022736"><span class="h1">PROPHYLAXIS</span><span class="headingEndMark"> — </span>Although there are no randomized trials that prove the value of early post-transplant systemic antimicrobial prophylaxis, it is typically administered.</p><p class="headingAnchor" id="H1627022748"><span class="h2">Systemic antibiotics</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis regimens should be chosen to broadly cover the common gram-positive and gram-negative pathogens associated with nosocomial infection at a particular institution and should also be tailored to cover likely pathogens in a given patient based on prior microbiology data and risk factors.</p><p class="headingAnchor" id="H13586165"><span class="h3">Routine perioperative prophylaxis</span><span class="headingEndMark"> — </span>We usually use a regimen of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> perioperatively to prevent bacterial infection. Initial doses are administered prior to incision, typically between arrival in the operating room and positioning the patient for surgery  (<a class="graphic graphic_table graphicRef78763" href="/z/d/graphic/78763.html" rel="external">table 3</a>). If cefepime is not available, alternative beta-lactams with anti-pseudomonal activity include <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> and <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>. Such a regimen is designed to cover methicillin-resistant <em>S. aureus</em> (MRSA) as well as <em>P. aeruginosa</em> and other gram-negative bacteria, although the specific regimen chosen depends upon local resistance patterns and the patient's microbiologic data. For patients undergoing lung transplantation for cystic fibrosis (CF), in particular, the regimen should be tailored to cover the susceptibility patterns of the known pretransplant pathogens. For patients whose chest remains open post-transplant, we add a systemic antifungal agent that treats <em>Candida</em> species (eg, an echinocandin, such as <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a>).</p><p>The optimal duration of antimicrobial prophylaxis is uncertain, varies at different transplant centers, but generally ranges from 72 hours to 7 days and is determined based upon several patient-specific factors. For patients without septic lung disease (eg, cystic fibrosis) who have an uncomplicated course following transplantation, we typically continue systemic antibacterial prophylaxis for 72 hours to allow time to determine whether donor cultures are positive. We generally continue prophylaxis against gram-positive organisms, particularly MRSA, as long as chest tubes remain in place. For a patient whose chest remains open following transplantation, we continue antimicrobial prophylaxis until the chest is closed. (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Prophylaxis'</a>.) .</p><p class="headingAnchor" id="H4589847"><span class="h3">Trimethoprim-sulfamethoxazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX), which is the agent of choice for <em>P. jirovecii</em> (formerly <em>P. carinii</em>) pneumonia prophylaxis, has the added benefit of having activity against various other pathogens such as <em>S. pneumoniae</em>, <em>L. monocytogenes</em>, and <em>Toxoplasma gondii</em>. It also has activity against <em>Nocardia</em> spp, although cases of nocardiosis have occurred in solid organ transplant recipients receiving TMP-SMX prophylaxis. TMP-SMX should be started within one week postoperatively. The usual dosing is one double-strength tablet daily or three times per week or one single-strength tablet orally daily, continued indefinitely  (<a class="graphic graphic_table graphicRef78763" href="/z/d/graphic/78763.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Pneumocystis pneumonia'</a>.)</p><p class="headingAnchor" id="H13586129"><span class="h2">Positive lung cultures</span><span class="headingEndMark"> — </span>When cultures are positive from either the donor lung at the time of transplantation or from the native lungs either from the pretransplant period or from the time of transplantation, treatment is advisable to prevent the development of anastomotic complications, pneumonia, and thoracic space infections.</p><p class="headingAnchor" id="H13586136"><span class="h3">Positive donor lung cultures</span><span class="headingEndMark"> — </span>Bronchial washings are routinely obtained from the donor lungs for Gram stain and culture during transplantation. When such cultures are positive, the lung transplant recipient is usually treated with antimicrobial agents that target the isolated species. Lung transplant recipients should generally be treated for two weeks with directed antibacterial therapy against <em>S. aureus</em> or gram-negative bacilli when one of these pathogens is isolated from the donor lung(s) [<a href="#rid72">72</a>]. A shorter course is reasonable when less virulent bacteria are detected.</p><p class="headingAnchor" id="H162322"><span class="h3">Positive native lung cultures</span><span class="headingEndMark"> — </span>In patients colonized pretransplant with multidrug-resistant bacteria, such as <em>P. aeruginosa</em> or <em>B. cepacia</em>, aggressive antimicrobial prophylaxis with multiple agents from different classes is administered during the post-transplant period. The specific regimen depends upon the resistance patterns of the individual patient's isolates. Durations of IV antibiotics of two to three weeks are typical for most infections excluding <em>B. cepacia</em>, which requires a longer duration. (See <a class="local">'Burkholderia cepacia'</a> above and <a class="local">'Pseudomonas aeruginosa'</a> above.)</p><p>As discussed above, <em>B. cenocepacia</em> is associated with significantly worse post-transplant survival compared with CF patients not colonized with this organism [<a href="#rid52">52,56,73-75</a>]. For this reason, colonization with <em>B. cenocepacia</em> is considered a relative contraindication to transplantation and is generally performed only at a limited number of transplant centers with experience managing such patients. (See <a class="local">'Burkholderia cepacia'</a> above.)</p><p class="headingAnchor" id="H1627022761"><span class="h2">Adjunctive strategies</span><span class="headingEndMark"> — </span>Adjunctive approaches to systemic antibiotics include inhaled antimicrobial agents and removal of potential infectious reservoirs. While the role of inhaled antibiotics such as aminoglycosides has not been rigorously studied, the potential to decrease colonization of the allograft with minimal systemic toxicity may be an appealing strategy in patients at high risk for multidrug-resistant organisms, such as <em>Pseudomonas</em> and <em>Burkholderia</em> spp.</p><p>The use of inhaled aminoglycosides in addition to systemic therapy is often used for patients with cystic fibrosis or other septic lung disease in which patients are known to be colonized with gram-negative bacteria prior to transplant. Inhaled aminoglycosides are also frequently used post-transplant for multidrug-resistant gram-negative infections in any host.</p><p>Other prophylactic measures include clearance of the bacterial reservoir in the sinuses of patients with CF or other ciliary function defects. The sinuses serve as a major reservoir for bacterial pathogens in patients with CF. There are conflicting data regarding whether pretransplant sinus surgery decreases the incidence of bacterial colonization of the lungs, tracheobronchitis, or pneumonia after lung transplantation [<a href="#rid76">76,77</a>]. The American Society of Transplantation therefore does not recommend routine pretransplant surgery [<a href="#rid51">51</a>].</p><p>Central venous catheters should be removed as early as possible post-transplant to limit the risk of bloodstream infection.</p><p class="headingAnchor" id="H1627022774"><span class="h1">VACCINATION</span><span class="headingEndMark"> — </span>Prevention of infection is of paramount importance to the lung transplant recipient. Infection in these patients results in excessive morbidity and mortality, and antimicrobial therapy is often less effective than in the immunocompetent host. Although immunization appears to be an obvious way to prevent infection, many immunocompromised patients are unable to mount protective immune responses.</p><p>Lung transplant candidates often have to wait unpredictable periods before a suitable donor is available. This waiting period should be used to maintain or boost antibody concentrations for all age-, exposure history-, and immune status-appropriate vaccines  (<a class="graphic graphic_table graphicRef91883" href="/z/d/graphic/91883.html" rel="external">table 4</a>) [<a href="#rid78">78</a>]. The timing of resuming vaccinations post-transplant and other issues related to immunizations in solid organ transplant candidates and recipients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H2345353080"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117424.html" rel="external">"Society guideline links: Infections in solid organ transplant recipients"</a>.)</p><p class="headingAnchor" id="H1627022787"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risk of infection</strong> − Lung transplant recipients are at increased risk for infectious complications due to the high level of immunosuppression required to prevent rejection, adverse effects of transplantation on local pulmonary host defenses (eg, reduced mucociliary clearance), and constant environmental contact allowing pathogens direct access into the allograft. (See <a class="local">'Risk of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common infections</strong> − Pneumonia is the most common type of infection in lung transplant recipients, although bloodstream, pleural space, and wound infections are also common. (See <a class="local">'Risk of infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific risks with cystic fibrosis</strong> − Patients with cystic fibrosis (CF) have unique risk factors for infection following transplantation. In particular, patients with CF are often colonized with such gram-negative bacteria as <em>Pseudomonas aeruginosa</em> and <em>Burkholderia cepacia</em>, both of which are frequently multidrug resistant. (See <a class="local">'Specific pathogens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of bacterial pneumonia</strong> − Patients <strong>suspected</strong> of having bacterial pneumonia should be treated empirically with broad-spectrum antibiotics, taking into account prior infections and colonization as well as other likely potential pathogens, including methicillin-resistant <em>Staphylococcus aureus </em>(MRSA), <em>P. aeruginosa</em>, other gram-negative bacilli, and atypical bacteria (eg, <em>Mycoplasma pneumoniae</em>, <em>Legionella</em> spp). The treatment duration in lung transplant recipients with uncomplicated bacterial pneumonia should generally be two weeks. (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative antibacterial prophylaxis</strong> − We recommend perioperative antibacterial prophylaxis for all lung transplant recipients (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). For routine perioperative antibacterial prophylaxis in lung transplant recipients, we favor <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, although the choice of regimen should be based upon local resistance patterns and the patient's microbiologic data. For patients without septic lung disease who have an uncomplicated course following transplantation, we typically continue systemic antibacterial prophylaxis for at least 72 hours. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of bacteria isolated from donor lungs</strong> − When <em>S. aureus</em> or gram-negative bacilli are isolated from the donor lung(s), we recommend that lung transplant recipients be treated with directed antibacterial therapy against the species isolated (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). We favor a two-week course of antibiotics for these bacteria. (See <a class="local">'Positive donor lung cultures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of bacteria isolated from native lungs</strong> − In patients colonized pretransplant with multidrug-resistant bacteria, such as <em>P. aeruginosa</em> or <em>B. cepacia</em>, aggressive antimicrobial prophylaxis with multiple agents from different classes is administered during the post-transplant period. The specific regimen depends upon the resistance patterns of the individual patient's isolates. Durations of intravenous antibiotics of two to three weeks are typical for most infections excluding <em>B. cepacia</em>, which requires a longer duration. (See <a class="local">'Positive native lung cultures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-transplant antibacterial prophylaxis</strong> − We recommend <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> for <em>Pneumocystis</em> prophylaxis (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>); in addition to anti-<em>Pneumocystis</em> activity, trimethoprim-sulfamethoxazole also has activity against <em>Streptococcus pneumoniae</em>, <em>Listeria</em>, <em>Nocardia</em>, and <em>Toxoplasma</em> spp. The usual dosing is one double-strength tablet daily or three times per week or one single-strength tablet daily, continued indefinitely. (See <a class="local">'Prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for </strong><strong><em>Burkholderia cenocepacia</em></strong> − All patients with cystic fibrosis should be screened for <em>B. cenocepacia</em> prior to transplantation. Colonization with this strain is viewed as a relative contraindication to transplantation. (See <a class="local">'Burkholderia cepacia'</a> above and <a class="local">'Positive native lung cultures'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Valapour M, Skeans MA, Smith JM, et al. OPTN/SRTR Annual Data Report 2014: Lung. Am J Transplant 2016; 16:141.</a></li><li><a class="nounderline abstract_t">Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33:1009.</a></li><li><a class="nounderline abstract_t">Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009; 6:94.</a></li><li class="breakAll">Gavalda J, Roman A, Pahissa A. Risks and epidemiology of infections after lung or heart-lung transplantation. In: Transplant Infections, 3rd ed, Bowden RA, Ljungman P, Snydman DR (Eds), Lippincott Williams and Wilkins, 2010. p.114.</li><li><a class="nounderline abstract_t">Kulkarni HS, Cherikh WS, Chambers DC, et al. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis. J Heart Lung Transplant 2019; 38:5.</a></li><li><a class="nounderline abstract_t">Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002; 17:310.</a></li><li><a class="nounderline abstract_t">Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation. Am J Transplant 2015; 15:3024.</a></li><li><a class="nounderline abstract_t">Adegunsoye A, Strek ME, Garrity E, et al. Comprehensive Care of the Lung Transplant Patient. Chest 2017; 152:150.</a></li><li><a class="nounderline abstract_t">Zaas AK, Alexander BD. New developments in the diagnosis and treatment of infections in lung transplant recipients. Respir Care Clin N Am 2004; 10:531.</a></li><li><a class="nounderline abstract_t">Paglicci L, Borgo V, Lanzarone N, et al. Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients. Eur J Clin Microbiol Infect Dis 2021; 40:1271.</a></li><li><a class="nounderline abstract_t">Nunley DR, Grgurich W, Iacono AT, et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998; 113:1235.</a></li><li><a class="nounderline abstract_t">Ruiz I, Gavaldà J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 2006; 6:178.</a></li><li><a class="nounderline abstract_t">Aguilar-Guisado M, Givaldá J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007; 7:1989.</a></li><li><a class="nounderline abstract_t">Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002; 21:555.</a></li><li><a class="nounderline abstract_t">Lyon GM, Alspaugh JA, Meredith FT, et al. Mycoplasma hominis pneumonia complicating bilateral lung transplantation: case report and review of the literature. Chest 1997; 112:1428.</a></li><li><a class="nounderline abstract_t">Matson KM, Sonetti DA. Successful treatment of Ureaplasma-induced hyperammonemia syndrome post-lung transplant. Transpl Infect Dis 2019; 21:e13022.</a></li><li><a class="nounderline abstract_t">Poonyagariyagorn HK, Gershman A, Avery R, et al. Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients. Transpl Infect Dis 2008; 10:403.</a></li><li><a class="nounderline abstract_t">Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.</a></li><li><a class="nounderline abstract_t">Clark NM, Reid GE, AST Infectious Diseases Community of Practice. Nocardia infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:83.</a></li><li><a class="nounderline abstract_t">Goodlet KJ, Tokman S, Nasar A, et al. Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: A matched case-control study. Transpl Infect Dis 2021; 23:e13478.</a></li><li><a class="nounderline abstract_t">Smibert OC, Wilson HL, Sohail A, et al. Donor-Derived Mycoplasma hominis and an Apparent Cluster of M. hominis Cases in Solid Organ Transplant Recipients. Clin Infect Dis 2017; 65:1504.</a></li><li><a class="nounderline abstract_t">Ramos KJ, Sykes J, Stanojevic S, et al. Survival and Lung Transplant Outcomes for Individuals With Advanced Cystic Fibrosis Lung Disease Living in the United States and Canada: An Analysis of National Registries. Chest 2021; 160:843.</a></li><li><a class="nounderline abstract_t">Shoham S, Shah PD. Impact of multidrug-resistant organisms on patients considered for lung transplantation. Infect Dis Clin North Am 2013; 27:343.</a></li><li><a class="nounderline abstract_t">Judson MA, Handy JR, Sahn SA. Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications. Chest 1996; 109:1190.</a></li><li><a class="nounderline abstract_t">Nunley DR, Grgurich WF, Keenan RJ, Dauber JH. Empyema complicating successful lung transplantation. Chest 1999; 115:1312.</a></li><li><a class="nounderline abstract_t">Herridge MS, de Hoyos AL, Chaparro C, et al. Pleural complications in lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:22.</a></li><li><a class="nounderline abstract_t">Rappaport JM, Siddiqui HU, Tang A, et al. Pleural space management after lung transplant: Early and late outcomes of pleural decortication. J Heart Lung Transplant 2021; 40:623.</a></li><li><a class="nounderline abstract_t">Tang A, Siddiqui HU, Thuita L, et al. Natural History of Pleural Complications After Lung Transplantation. Ann Thorac Surg 2021; 111:407.</a></li><li><a class="nounderline abstract_t">Joean O, Kayser MZ, Valtin C, et al. Characteristics and clinical implications of pleural effusions after lung transplantation: A retrospective analysis of 195 thoracocenteses in 113 patients. Clin Transplant 2021; 35:e14267.</a></li><li><a class="nounderline abstract_t">Backhus LM, Sievers EM, Schenkel FA, et al. Pleural space problems after living lobar transplantation. J Heart Lung Transplant 2005; 24:2086.</a></li><li><a class="nounderline abstract_t">Wahidi MM, Willner DA, Snyder LD, et al. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135:484.</a></li><li><a class="nounderline abstract_t">Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163:43.</a></li><li><a class="nounderline abstract_t">Janssens W, Van Raemdonck D, Dupont L, Verleden GM. Listeria pleuritis 1 week after lung transplantation. J Heart Lung Transplant 2006; 25:734.</a></li><li><a class="nounderline abstract_t">Husain S, Chan KM, Palmer SM, et al. Bacteremia in lung transplant recipients in the current era. Am J Transplant 2006; 6:3000.</a></li><li><a class="nounderline abstract_t">Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000; 69:2360.</a></li><li><a class="nounderline abstract_t">Danziger-Isakov LA, Sweet S, Delamorena M, et al. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J 2005; 24:324.</a></li><li><a class="nounderline abstract_t">Routledge T, Saeb-Parsy K, Murphy F, Ritchie AJ. The use of vacuum-assisted closure in the treatment of post-transplant wound infections: a case series. J Heart Lung Transplant 2005; 24:1444.</a></li><li><a class="nounderline abstract_t">Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14:452.</a></li><li><a class="nounderline abstract_t">Dupont L. Lung transplantation in cystic fibrosis patients with difficult to treat lung infections. Curr Opin Pulm Med 2017; 23:574.</a></li><li><a class="nounderline abstract_t">Mitsani D, Nguyen MH, Silveira FP, et al. Mycoplasma hominis pericarditis in a lung transplant recipient: review of the literature about an uncommon but important cardiothoracic pathogen. Transpl Infect Dis 2010; 12:146.</a></li><li><a class="nounderline abstract_t">Vecchio M, Koutsokera A, Touilloux B, et al. Bronchial anastomosis dehiscence and stenosis caused by donor-transmitted Mycoplasma hominis infection in a lung transplant recipient: Case report and literature review. Transpl Infect Dis 2021; 23:e13475.</a></li><li><a class="nounderline abstract_t">Leger RF, Silverman MS, Hauck ES, Guvakova KD. Hyperammonemia Post Lung Transplantation: A Review. Clin Med Insights Circ Respir Pulm Med 2020; 14:1179548420966234.</a></li><li><a class="nounderline abstract_t">Kotsimbos TC, Snell GI, Levvey B, et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2005; 79:269.</a></li><li><a class="nounderline abstract_t">Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85:771.</a></li><li><a class="nounderline abstract_t">Combs MP, Wheeler DS, Luth JE, et al. Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study. Lancet Respir Med 2021; 9:601.</a></li><li><a class="nounderline abstract_t">Kanj SS, Tapson V, Davis RD, et al. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997; 112:924.</a></li><li><a class="nounderline abstract_t">Aris RM, Gilligan PH, Neuringer IP, et al. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155:1699.</a></li><li><a class="nounderline abstract_t">Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004; 56:277.</a></li><li><a class="nounderline abstract_t">Pritchard J, Thakrar MV, Somayaji R, et al. Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation. J Cyst Fibros 2016; 15:392.</a></li><li><a class="nounderline abstract_t">Srour N, Chaparro C, Vandemheen K, et al. Effect of infection with transmissible strains of Pseudomonas aeruginosa on lung transplantation outcomes in patients with cystic fibrosis. J Heart Lung Transplant 2015; 34:588.</a></li><li><a class="nounderline abstract_t">van Delden C, Blumberg EA, AST Infectious Diseases Community of Practice. Multidrug resistant gram-negative bacteria in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S27.</a></li><li><a class="nounderline abstract_t">Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025.</a></li><li><a class="nounderline abstract_t">Wang R, Welsh SK, Budev M, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia dolosa (genomovar VI). Clin Transplant 2018; 32:e13236.</a></li><li><a class="nounderline abstract_t">Mitchell AB, Glanville AR. The Impact of Resistant Bacterial Pathogens including Pseudomonas aeruginosa and Burkholderia on Lung Transplant Outcomes. Semin Respir Crit Care Med 2021; 42:436.</a></li><li><a class="nounderline abstract_t">De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29:1395.</a></li><li><a class="nounderline abstract_t">Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63:732.</a></li><li><a class="nounderline abstract_t">Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33:1469.</a></li><li><a class="nounderline abstract_t">van Duin D, van Delden C, AST Infectious Diseases Community of Practice. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:31.</a></li><li><a class="nounderline abstract_t">Garzoni C, Vergidis P, AST Infectious Diseases Community of Practice. Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:50.</a></li><li><a class="nounderline abstract_t">de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.</a></li><li><a class="nounderline abstract_t">Glanville AR, Gencay M, Tamm M, et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005; 24:131.</a></li><li><a class="nounderline abstract_t">Husain S, McCurry K, Dauber J, et al. Nocardia infection in lung transplant recipients. J Heart Lung Transplant 2002; 21:354.</a></li><li><a class="nounderline abstract_t">Dubberke ER, Riddle DJ, AST Infectious Diseases Community of Practice. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S35.</a></li><li><a class="nounderline abstract_t">Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:592.</a></li><li><a class="nounderline abstract_t">Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One 2015; 10:e0124483.</a></li><li><a class="nounderline abstract_t">Whiddon AR, Dawson KL, Fuentes A, et al. Postoperative antimicrobials after lung transplantation and the development of multidrug-resistant bacterial and Clostridium difficile infections: an analysis of 500 non-cystic fibrosis lung transplant patients. Clin Transplant 2016; 30:767.</a></li><li><a class="nounderline abstract_t">Lee JT, Kelly RF, Hertz MI, et al. Clostridium difficile infection increases mortality risk in lung transplant recipients. J Heart Lung Transplant 2013; 32:1020.</a></li><li><a class="nounderline abstract_t">Jankovic Makek M, Pavlisa G, Jakopovic M, et al. Early onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature. Transpl Infect Dis 2016; 18:112.</a></li><li><a class="nounderline abstract_t">Longworth SA, Vinnard C, Lee I, et al. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis 2014; 16:76.</a></li><li><a class="nounderline abstract_t">Lobo LJ, Chang LC, Esther CR Jr, et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013; 27:523.</a></li><li><a class="nounderline abstract_t">Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; :CD007577.</a></li><li><a class="nounderline abstract_t">Fischer SA, Avery RK, AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9 Suppl 4:S7.</a></li><li><a class="nounderline abstract_t">Snell GI, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103:466.</a></li><li><a class="nounderline abstract_t">Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164:2102.</a></li><li><a class="nounderline abstract_t">De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358:1780.</a></li><li><a class="nounderline abstract_t">Holzmann D, Speich R, Kaufmann T, et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation 2004; 77:134.</a></li><li><a class="nounderline abstract_t">Leung MK, Rachakonda L, Weill D, Hwang PH. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol 2008; 22:192.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li></ol></div><div id="topicVersionRevision">Topic 1395 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : OPTN/SRTR Annual Data Report 2014: Lung</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242125" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131534" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infections relevant to lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131534" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infections relevant to lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30391193" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12497548" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474168" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27729262" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comprehensive Care of the Lung Transplant Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585181" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New developments in the diagnosis and treatment of infections in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33479881" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596300" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433772" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Donor-to-host transmission of bacterial and fungal infections in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617864" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11983545" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A positive donor gram stain does not predict outcome following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367488" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mycoplasma hominis pneumonia complicating bilateral lung transplantation: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30403322" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Successful treatment of Ureaplasma-induced hyperammonemia syndrome post-lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823356" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443467" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465002" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nocardia infections in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32989873" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: A matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29048510" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Donor-Derived Mycoplasma hominis and an Apparent Cluster of M. hominis Cases in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33878343" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Survival and Lung Transplant Outcomes for Individuals With Advanced Cystic Fibrosis Lung Disease Living in the United States and Canada: An Analysis of National Registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23714344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Impact of multidrug-resistant organisms on patients considered for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625665" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334145" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Empyema complicating successful lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7541881" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pleural complications in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33994081" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pleural space management after lung transplant: Early and late outcomes of pleural decortication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853567" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Natural History of Pleural Complications After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33615592" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characteristics and clinical implications of pleural effusions after lung transplantation: A retrospective analysis of 195 thoracocenteses in 113 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364854" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pleural space problems after living lobar transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017896" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis and outcome of early pleural space infection following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208624" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16730581" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Listeria pleuritis 1 week after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17294526" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bacteremia in lung transplant recipients in the current era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868641" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818292" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Epidemiology of bloodstream infections in the first year after pediatric lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143271" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The use of vacuum-assisted closure in the treatment of post-transplant wound infections: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22676720" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28858970" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Lung transplantation in cystic fibrosis patients with difficult to treat lung infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19781019" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mycoplasma hominis pericarditis in a lung transplant recipient: review of the literature about an uncommon but important cardiothoracic pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978884" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bronchial anastomosis dehiscence and stenosis caused by donor-transmitted Mycoplasma hominis infection in a lung transplant recipient: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33192115" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hyperammonemia Post Lung Transplantation: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699755" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337673" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33460570" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9377954" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infections in patients with cystic fibrosis following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154879" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15066737" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26657575" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455752" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effect of infection with transmissible strains of Pseudomonas aeruginosa on lung transplantation outcomes in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070690" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multidrug resistant gram-negative bacteria in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18318775" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29528522" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia dolosa (genomovar VI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34030205" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Impact of Resistant Bacterial Pathogens including Pseudomonas aeruginosa and Burkholderia on Lung Transplant Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810293" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408050" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11588691" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464996" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Multidrug-resistant gram-negative bacteria infections in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464998" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15268742" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Invasive pneumococcal infections in adult lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701426" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Chlamydia pneumoniae infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897524" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nocardia infection in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070693" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clostridium difficile in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060548" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clostridium difficile infection in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25886133" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27091109" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Postoperative antimicrobials after lung transplantation and the development of multidrug-resistant bacterial and Clostridium difficile infections: an analysis of 500 non-cystic fibrosis lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891145" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clostridium difficile infection increases mortality risk in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26556693" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Early onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24350627" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23710571" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26301604" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20070698" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Screening of donor and recipient prior to solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7679347" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pseudomonas cepacia in lung transplant recipients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739142" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11734238" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724449" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18416979" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
